This technology relates to a class of synthetic peptides with antimicrobial activity. The lead candidate identified among this class is EC5. The EC5 peptide has shown efficient binding and selective bactericidal activity against E. coli and P. aeruginosa, while having little activity against S. aureus, S. epidermidis, B. cereus, and K. pneumonia. EC5 shows inhibitory activity at low concentrations (MIC 8 µg/ml for E. coli and 8-32 µg/ml for P. aeruginosa) and appears to bind to, disrupt, and permeabilize the bacterial cell membranes in a manner similar to Polymyxin B. EC5 also appears to retain its bactericidal activity in the presence of platelets and plasma, while exhibiting little cytotoxic activity or hemolytic activity against red blood cells, in vitro. EC5's profile of activity and low toxicity suggest it may be a favorable candidate for drug development, as an independent or combination therapy and for specific bacterial detection/diagnostics. With the increasing prevalence of drug resistant bacterial infections, there is a need to develop novel antimicrobial agents that are specific, safe, and effective.
Potential Commercial Applications:
- Antimicrobial therapy
- Significant and specific bactericidal activity
- Promising in vitro safety profile
Shilpakala Sainath Rao
PCT Application No. PCT/US2012/050969
Sainath Rao S, et al. PMID 23409125
The Food and Drug Administration, Center for Biologics Evaluation and Research, is seeking statements of capability or interest from parties interested in collaborative research to further develop, evaluate or commercialize drug development, as an independent or combination therapy and for bacterial diagnostics. For collaboration opportunities, please contact Nisha Narayan at 240-402-9770.
Bill Ronnenberg, JD-MIP, MS
FDA Technology Transfer Program
10903 New Hampshire Ave.
Building WO1, Rm 4214
Silver Spring, MD 20993
OTT Reference No: E-226-2012/0
Updated: August 4, 2015